Tuesday 22 July 2014

Puma says cancer drug meets trial goal, shares soar

(Reuters) - Puma Biotechnology Inc said its experimental cancer drug met its main goal in a late-stage trial, sending its shares up about 186 percent in extended trading. The drug neratinib, codenamed PB272, is being studied as a potential adjuvant treatment for breast cancer. Adjuvant treatment, or additional treatment, is given after the primary treatment. The patients were treated with neratinib after adjuvant treatment with the cancer drug trastuzumab in women with early-stage HER2-positive breast cancer. via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment